Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy
Tommaso Morelli, Kohei Fujita, Gil Redelman‐Sidi, et al.
Thorax (2021) Vol. 77, Iss. 3, pp. 304-311
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Antibiotic failure: Beyond antimicrobial resistance
César de la Fuente‐Núñez, Angela Cesaro, Robert E. W. Hancock
Drug Resistance Updates (2023) Vol. 71, pp. 101012-101012
Closed Access | Times Cited: 97
Immune checkpoint blockade in experimental bacterial infections
Nicole Lind Henriksen, Peter Østrup Jensen, Louise Kruse Jensen
Journal of Infection (2025), pp. 106391-106391
Open Access | Times Cited: 1
Unintended Consequences: Risk of Opportunistic Infections Associated With Long-term Glucocorticoid Therapies in Adults
Daniel B. Chastain, Megan Spradlin, Hiba Ahmad, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 4, pp. e37-e56
Open Access | Times Cited: 16
Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database
Shuang Xia, Hui Gong, Yikun Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?
Akshara Vaddi, Holly J. Hulsebus, Emily L. O’Neill, et al.
Journal of Thoracic Disease (2024) Vol. 16, Iss. 2, pp. 1601-1624
Open Access | Times Cited: 5
Construction of a risk prediction model for lung infection after chemotherapy in lung cancer patients based on the machine learning algorithm
Tao Sun, Jun Liu, Houqin Yuan, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
What should intensivists know about immune checkpoint inhibitors and their side effects?
В. Г. Александров, F. Martínez Sagasti, J.A Ruíz Moreno, et al.
Medicina Intensiva (English Edition) (2025), pp. 502135-502135
Closed Access
Population-Based Analysis of the Risk of Mycobacterial Infections Associated With Immune Checkpoint Inhibitors
Marie Yan, Alejandro Hernandez, Kelvin Chan, et al.
Clinical Infectious Diseases (2025)
Closed Access
Incidence and risk factors of serious infections occurred in patients with lung cancer following immune checkpoint blockade therapy
Xiao Wang, Yuxiao Wu, Weiping Hu, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Type I Diabetes—A Rare Adverse Event Described in Patients Receiving Immunotherapy Versus a Side Effect from SARS-CoV-2 Infection
Raluca-Ileana Pătru, Miruna Ghigeanu, Maria-Alexandra Barbu, et al.
Reports — Medical Cases Images and Videos (2025) Vol. 8, Iss. 1, pp. 31-31
Open Access
The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy
Shuguang Zhang, Wen‐Ying Chen, Jihong Zhou, et al.
Journal of Inflammation Research (2025) Vol. Volume 18, pp. 4335-4357
Open Access
Where lung cancer and tuberculosis intersect: recent advances
Chunju Fang, Xuanlu He, Fei Tang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
A rapidly progressive case of tuberculous pleurisy and pericarditis in a patient with non-small cell lung cancer that developed one month after receiving pembrolizumab monotherapy
Saori Ikeda, Kageaki Watanabe, Kazuhito Misawa, et al.
IDCases (2025), pp. e02234-e02234
Open Access
Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections
Kohei Fujita, Paul Elkington
Respiratory Investigation (2024) Vol. 62, Iss. 3, pp. 339-347
Closed Access | Times Cited: 3
Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling
Masato Ogishi, Koji Kitaoka, Kim L. Good‐Jacobson, et al.
Immunity (2024) Vol. 57, Iss. 12, pp. 2790-2807.e15
Closed Access | Times Cited: 3
Understanding the tuberculosis granuloma: the matrix revolutions
Paul Elkington, Marta E. Polak, Michaela T. Reichmann, et al.
Trends in Molecular Medicine (2021) Vol. 28, Iss. 2, pp. 143-154
Open Access | Times Cited: 23
An Overview of Selected Bacterial Infections in Cancer, Their Virulence Factors, and Some Aspects of Infection Management
Amitabha Ray, Thomas Moore, Rajashree Pandit, et al.
Biology (2023) Vol. 12, Iss. 7, pp. 963-963
Open Access | Times Cited: 9
Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: Recent advances and future Directions
Ling Yang, Zhuang Li, Zhaoyang Ye, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107881-107881
Open Access | Times Cited: 9
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives
Trilok Shrivastava, Frits van Rhee, Samer Al Hadidi
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 441-464
Open Access | Times Cited: 8
CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review
Erum Khan, Ashish Shrestha, Mahmoud Elkhooly, et al.
Journal of the Neurological Sciences (2021) Vol. 432, pp. 120089-120089
Closed Access | Times Cited: 19
How and when to manage respiratory infections out of hospital
Rodrigo Cavallazzi, Julio A. Ramírez
European Respiratory Review (2022) Vol. 31, Iss. 166, pp. 220092-220092
Open Access | Times Cited: 14
Clinical Characteristics and Outcomes of Gastritis Associated With Immune Checkpoint Inhibitors: Scoping Review
Adham E Obeidat, Krixie Silangcruz, Landon Kozai, et al.
Journal of Immunotherapy (2022) Vol. 45, Iss. 8, pp. 363-369
Closed Access | Times Cited: 12
Serial interferon-gamma release assay in lung cancer patients receiving immune checkpoint inhibitors: a prospective cohort study
Kohei Fujita, Paul Elkington, Gil Redelman‐Sidi, et al.
Cancer Immunology Immunotherapy (2022) Vol. 71, Iss. 11, pp. 2757-2764
Open Access | Times Cited: 11
Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study
Shuang Xia, Hui Gong, Yi‐Chang Zhao, et al.
Cancers (2022) Vol. 15, Iss. 1, pp. 240-240
Open Access | Times Cited: 11
Dynamic immune signatures of patients with advanced non–small-cell lung cancer for infection prediction after immunotherapy
Yung‐Hung Luo, Chia‐I Shen, Chi‐Lu Chiang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top